vs

Side-by-side financial comparison of COMMVAULT SYSTEMS INC (CVLT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $313.8M, roughly 2.0× COMMVAULT SYSTEMS INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 5.7%, a 28.8% gap on every dollar of revenue. On growth, COMMVAULT SYSTEMS INC posted the faster year-over-year revenue change (19.5% vs 4.8%). Over the past eight quarters, COMMVAULT SYSTEMS INC's revenue compounded faster (18.6% CAGR vs 4.6%).

Commvault Systems, Inc. is an American publicly traded cybersecurity and data protection software company. Commvault's services are used for data security, as well as cloud and infrastructure management.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

CVLT vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
2.0× larger
RPRX
$622.0M
$313.8M
CVLT
Growing faster (revenue YoY)
CVLT
CVLT
+14.7% gap
CVLT
19.5%
4.8%
RPRX
Higher net margin
RPRX
RPRX
28.8% more per $
RPRX
34.4%
5.7%
CVLT
Faster 2-yr revenue CAGR
CVLT
CVLT
Annualised
CVLT
18.6%
4.6%
RPRX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CVLT
CVLT
RPRX
RPRX
Revenue
$313.8M
$622.0M
Net Profit
$17.8M
$214.2M
Gross Margin
81.1%
Operating Margin
6.3%
62.4%
Net Margin
5.7%
34.4%
Revenue YoY
19.5%
4.8%
Net Profit YoY
61.3%
2.9%
EPS (diluted)
$0.40
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVLT
CVLT
RPRX
RPRX
Q4 25
$313.8M
$622.0M
Q3 25
$276.2M
$609.3M
Q2 25
$282.0M
$578.7M
Q1 25
$275.0M
$568.2M
Q4 24
$262.6M
$593.6M
Q3 24
$233.3M
$564.7M
Q2 24
$224.7M
$537.3M
Q1 24
$223.3M
$568.0M
Net Profit
CVLT
CVLT
RPRX
RPRX
Q4 25
$17.8M
$214.2M
Q3 25
$14.7M
$288.2M
Q2 25
$23.5M
$30.2M
Q1 25
$31.0M
$238.3M
Q4 24
$11.0M
$208.2M
Q3 24
$15.6M
$544.0M
Q2 24
$18.5M
$102.0M
Q1 24
$126.1M
$4.8M
Gross Margin
CVLT
CVLT
RPRX
RPRX
Q4 25
81.1%
Q3 25
80.1%
Q2 25
82.0%
Q1 25
82.6%
Q4 24
81.5%
Q3 24
81.6%
Q2 24
82.3%
Q1 24
82.5%
Operating Margin
CVLT
CVLT
RPRX
RPRX
Q4 25
6.3%
62.4%
Q3 25
4.5%
70.1%
Q2 25
8.9%
36.3%
Q1 25
9.7%
94.0%
Q4 24
5.2%
60.9%
Q3 24
6.4%
Q2 24
8.2%
50.2%
Q1 24
8.1%
-13.0%
Net Margin
CVLT
CVLT
RPRX
RPRX
Q4 25
5.7%
34.4%
Q3 25
5.3%
47.3%
Q2 25
8.3%
5.2%
Q1 25
11.3%
41.9%
Q4 24
4.2%
35.1%
Q3 24
6.7%
96.3%
Q2 24
8.2%
19.0%
Q1 24
56.5%
0.8%
EPS (diluted)
CVLT
CVLT
RPRX
RPRX
Q4 25
$0.40
$0.49
Q3 25
$0.33
$0.67
Q2 25
$0.52
$0.07
Q1 25
$0.68
$0.55
Q4 24
$0.24
$0.46
Q3 24
$0.35
$1.21
Q2 24
$0.41
$0.23
Q1 24
$2.80
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVLT
CVLT
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$1.0B
$618.7M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$216.7M
$9.7B
Total Assets
$2.0B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVLT
CVLT
RPRX
RPRX
Q4 25
$1.0B
$618.7M
Q3 25
$1.1B
$938.9M
Q2 25
$363.2M
$631.9M
Q1 25
$302.1M
$1.1B
Q4 24
$243.6M
$929.0M
Q3 24
$303.1M
$950.1M
Q2 24
$287.9M
$1.8B
Q1 24
$312.8M
$843.0M
Total Debt
CVLT
CVLT
RPRX
RPRX
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
CVLT
CVLT
RPRX
RPRX
Q4 25
$216.7M
$9.7B
Q3 25
$210.5M
$9.6B
Q2 25
$364.7M
$9.5B
Q1 25
$325.1M
$9.8B
Q4 24
$287.8M
$10.3B
Q3 24
$277.8M
$10.3B
Q2 24
$281.8M
$9.8B
Q1 24
$278.1M
$9.9B
Total Assets
CVLT
CVLT
RPRX
RPRX
Q4 25
$2.0B
$19.6B
Q3 25
$1.9B
$19.3B
Q2 25
$1.2B
$18.3B
Q1 25
$1.1B
$17.6B
Q4 24
$1.0B
$18.2B
Q3 24
$958.5M
$18.0B
Q2 24
$934.9M
$17.7B
Q1 24
$943.9M
$16.1B
Debt / Equity
CVLT
CVLT
RPRX
RPRX
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVLT
CVLT
RPRX
RPRX
Operating Cash FlowLast quarter
$4.0M
$827.1M
Free Cash FlowOCF − Capex
$1.9M
FCF MarginFCF / Revenue
0.6%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
0.23×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$181.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVLT
CVLT
RPRX
RPRX
Q4 25
$4.0M
$827.1M
Q3 25
$76.8M
$702.6M
Q2 25
$31.7M
$364.0M
Q1 25
$77.0M
$596.1M
Q4 24
$30.1M
$742.5M
Q3 24
$55.6M
$703.6M
Q2 24
$44.7M
$658.2M
Q1 24
$80.0M
$664.6M
Free Cash Flow
CVLT
CVLT
RPRX
RPRX
Q4 25
$1.9M
Q3 25
$73.6M
Q2 25
$29.8M
Q1 25
$76.2M
Q4 24
$29.9M
Q3 24
$53.7M
Q2 24
$43.8M
Q1 24
$79.1M
FCF Margin
CVLT
CVLT
RPRX
RPRX
Q4 25
0.6%
Q3 25
26.6%
Q2 25
10.6%
Q1 25
27.7%
Q4 24
11.4%
Q3 24
23.0%
Q2 24
19.5%
Q1 24
35.4%
Capex Intensity
CVLT
CVLT
RPRX
RPRX
Q4 25
0.7%
Q3 25
1.2%
Q2 25
0.7%
Q1 25
0.3%
Q4 24
0.1%
Q3 24
0.8%
Q2 24
0.4%
Q1 24
0.4%
Cash Conversion
CVLT
CVLT
RPRX
RPRX
Q4 25
0.23×
3.86×
Q3 25
5.21×
2.44×
Q2 25
1.35×
12.06×
Q1 25
2.48×
2.50×
Q4 24
2.74×
3.57×
Q3 24
3.57×
1.29×
Q2 24
2.41×
6.45×
Q1 24
0.63×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVLT
CVLT

Term Based Software Licenses$119.0M38%
Software As A Service$87.4M28%
Customer Support Service$80.3M26%
Perpetual License$13.7M4%
Other$13.6M4%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons